Skip to content

T Cell Activation Bioassay (NFAT), Propagation Model

by Promega
€ 25,253.10

The T Cell Activation Bioassay, Propagation Model, provides a biologically relevant and specific MOA-based measure of TCR/CD3 Effector Cells without the complex workflow and variability inherent in primary cell-based assays. The T Cell Activation Bioassay, Propagation Model, allows propagation and banking of the TCR/CD3 Effector Cells. Bio-Glo Luciferase Assay System (Cat.# G7940, G7941) is the required reagent for use with the T Cell Activation Bioassay, Propagation Model. The T Cell Activation Bioassays are bioluminescent cell-based assays that overcome the limitations of existing assays and can be used for the discovery and development of novel biologics such as bispecific antibodies and CAR-T cell therapies. The assays consist of a genetically engineered Jurkat T cell line that expresses a luciferase reporter (TCR/CD3 Effector Cells) driven by either an NFAT-response element (NFAT-RE) or an IL-2 promoter. When the TCR/CD3 Effector Cells (NFAT) are engaged with an appropriate TCR/CD3 ligand or anti-TCR/CD3 antibody, the TCR transduces intracellular signals resulting in NFAT-RE-mediated luminescence. Similarly, when the TCR/CD3 Effector Cells (IL-2) are co-engaged with an anti-TCR/CD3 and an anti-CD28 stimulus, receptor-mediated signaling results in IL-2 promoter-mediated luminescence.